Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone and Canadian pension funds will invest $3.1 billion to buy 49.9% of Mitsubishi Corp.'s stake in LNG Canada. Mitsubishi retains 15% of the LNG export plant, which is expanding capacity to 28 million tonnes per year. LNG Canada is a $40 billion project led by Shell, with other partners including Petronas, PetroChina, and Korea Gas.

Boston Scientific and Blackstone Life Sciences agreed to a $455M partnership to develop a temporary heart pump for cardiogenic shock. The deal focuses on early-stage development with no clinical or commercial timelines disclosed.

Blackstone Life Sciences is investing $455 million in Boston Scientific to co-develop the VITALYST heart pump system for cardiogenic shock patients. The system aims to improve efficacy, safety, and ease of use. Blackstone highlights Boston Scientific's cardiovascular expertise and the potential of the VITALYST system to advance mechanical circulatory support technologies.

Blackstone Group (BX) completed a $1.1B senior notes offering on Nov 2, 2026, including $600M of 5.650% notes due 2031 and $500M of 5.900% notes due 2033. The notes are guaranteed by Blackstone and certain subsidiaries, with interest payable semiannually from May 3, 2027. Analysts rate BX stock as Buy with a $140 target, while Spark's AI rates it as Outperform.

Boston Scientific reported Q3 2026 revenue of $5.14B, up 1.4% YoY, but net income fell 22.9% to $582M due to a cybersecurity incident. EPS declined 21.6% to $0.4. Nine-month sales rose 6.7%, with Cardiovascular and MedSurg segments driving growth. The company expects to close its Penumbra acquisition in early 2027.

Blackstone issued $1.1 billion in senior notes, including $600 million of 5.650% notes due 2031 and $500 million of 5.900% notes due 2033. The unsecured notes are guaranteed by Blackstone and certain subsidiaries, providing long-term debt financing.